Dayvigo vs Trazodone: Cost and Access Head-to-Head

Pricing Breakdown: What Each Drug Actually Costs

The single biggest difference between these two medications is price. Trazodone, available as a generic since the early 1980s, is one of the cheapest prescription sleep aids on the U.S. Market. Dayvigo, a newer branded dual orexin receptor antagonist (DORA), carries the price tag typical of a patent-protected drug with no generic equivalent.

Retail Cash Prices

At retail pharmacies without insurance, a 30-day supply of trazodone 50 mg costs between $4 and $15 at most chains. GoodRx and similar discount programs often bring it below $10. A 30-day supply of Dayvigo 5 mg or 10 mg ranges from $400 to $520 depending on the pharmacy. That is roughly a 30- to 50-fold price difference [3].

Copay and Coupon Programs

Eisai, the manufacturer of Dayvigo, offers a commercial copay assistance card that can reduce out-of-pocket cost to $30 per month for patients with eligible commercial insurance [4]. Patients on Medicare, Medicaid, or other federal programs do not qualify for manufacturer copay cards under federal anti-kickback statutes. Trazodone rarely requires a coupon. Most patients pay $0 to $10 with any insurance plan.

Why the Price Gap Exists

Dayvigo received FDA approval in December 2019 and remains under patent protection with no authorized generic. Trazodone lost patent exclusivity decades ago, and multiple manufacturers produce it, which drives competition and suppresses pricing [5]. This is not a reflection of clinical value. It is a function of market dynamics.

Insurance Coverage and Formulary Access

Coverage determines what patients actually pay. Trazodone and Dayvigo sit in very different positions on most formularies, and that gap affects prescribing patterns.

Trazodone Coverage

Trazodone appears on Tier 1 (preferred generic) of nearly every commercial, Medicare Part D, Medicaid, and VA formulary in the United States. No prior authorization is required. No step therapy is imposed. Providers can prescribe it with minimal administrative friction. The VA National Formulary lists trazodone without restriction.

Dayvigo Coverage

Dayvigo typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) when it appears on a formulary at all. Many plans require prior authorization, and some impose step therapy requiring documented failure of a generic agent (often trazodone, zolpidem, or suvorexant) before approving Dayvigo. Medicare Part D plans vary widely. Some cover Dayvigo under Tier 3 with a $40 to $80 copay after prior authorization; others exclude it entirely and require a formulary exception request [6].

Practical Access Comparison

A patient with commercial PPO insurance can typically fill trazodone at any pharmacy within minutes of receiving the prescription. Dayvigo may require a 48- to 72-hour prior authorization review, a letter of medical necessity, and documentation of previous treatment failures. For patients without insurance, trazodone is accessible at $4 generic programs offered by Walmart, Costco, and other retailers. Dayvigo has no $4 option.

Clinical Efficacy: What the Trials Show

Comparing efficacy between Dayvigo and trazodone is complicated by a fundamental asymmetry. Dayvigo has strong Phase III trial data. Trazodone does not.

Dayvigo: The SUNRISE Program

The SUNRISE-1 trial (N=1,006) randomized adults aged 55 and older with insomnia to lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg, or placebo over 30 nights. Lemborexant 5 mg and 10 mg both significantly improved objective sleep onset latency (measured by polysomnography) compared to placebo. Lemborexant 10 mg also showed superiority to zolpidem ER for wake after sleep onset (WASO) in the second half of the night [1].

SUNRISE-2 (N=949) extended these findings over 12 months, demonstrating sustained efficacy in subjective sleep onset latency and sleep efficiency without evidence of rebound insomnia upon discontinuation [7]. Next-morning residual effects were minimal in both studies.

Trazodone: Off-Label With Thin RCT Support

Trazodone is the most prescribed medication for insomnia in the United States, yet it has never received FDA approval for this indication. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline noted that the evidence for trazodone in chronic insomnia is "very low quality" and issued a conditional recommendation against its use for sleep-onset or sleep-maintenance insomnia [8].

Mendelson's 2005 review in the Journal of Clinical Psychiatry examined the limited controlled data available and found that most studies were small, short-duration (one to two weeks), and primarily conducted in depressed populations rather than primary insomnia patients [2]. A 2017 Cochrane-eligible systematic review identified only minimal placebo-controlled data supporting trazodone's hypnotic efficacy [9].

Head-to-Head Data

No published randomized controlled trial has directly compared lemborexant to trazodone. Any efficacy comparison between the two drugs relies on indirect, cross-trial inference. Given differences in patient populations, endpoints, and study designs, direct comparison should be interpreted with caution.

Mechanism of Action: Different Pharmacological Targets

These drugs work through entirely different mechanisms, which explains their distinct side-effect profiles and clinical characteristics.

Dayvigo: Orexin Receptor Antagonism

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks orexin-A and orexin-B signaling at OX1R and OX2R receptors in the lateral hypothalamus, suppressing the wake-promoting drive rather than inducing sedation through GABA modulation. This mechanism preserves more normal sleep architecture compared to benzodiazepine receptor agonists [10].

Trazodone: Serotonin Antagonism and Histamine Blockade

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). Its sedative effect at low doses (25 mg to 100 mg) comes primarily from potent histamine H1 receptor antagonism and 5-HT2A receptor blockade, not from serotonin reuptake inhibition (which requires higher antidepressant doses of 150 mg to 300 mg). At hypnotic doses, trazodone functions more like an antihistamine than an antidepressant [11].

Clinical Implications of Mechanism Differences

The orexin system governs wakefulness without broadly suppressing CNS function. Patients on Dayvigo tend to report fewer hangover-type effects and less cognitive impairment the next morning compared to older hypnotics. Trazodone's antihistaminic sedation can produce morning grogginess, dry mouth, and orthostatic hypotension, particularly in older adults [12]. Trazodone carries a small risk of priapism (estimated at 1 in 6,000 to 1 in 8,000 male patients), a urologic emergency [2].

Side-Effect Profiles Compared

Both drugs are generally well-tolerated at standard hypnotic doses, but their adverse-event patterns differ.

Common Dayvigo Side Effects

In SUNRISE-1 and SUNRISE-2, the most frequently reported adverse events with lemborexant 5 mg and 10 mg included somnolence (reported in 7% to 10% of patients vs. 1% to 2% for placebo), headache, and unusual dreams. Sleep paralysis and hypnagogic hallucinations occurred rarely but are class effects of orexin receptor antagonists. No evidence of physical dependence or withdrawal was observed, though Dayvigo is classified as Schedule IV due to theoretical abuse potential shared across the DORA class [1][7].

Common Trazodone Side Effects

At doses of 25 mg to 100 mg used for sleep, trazodone commonly causes daytime drowsiness (especially at doses above 50 mg), dry mouth, dizziness, and orthostatic hypotension. The orthostatic effect is particularly concerning in elderly patients, where it increases fall risk. Cardiac effects including QT prolongation have been reported at higher antidepressant doses but are uncommon at hypnotic doses [13]. Weight gain is minimal with trazodone at low doses, which distinguishes it from other sedating antidepressants.

Safety in Older Adults

The American Geriatrics Society Beers Criteria does not list trazodone as a drug to avoid in older adults, though its anticholinergic and alpha-blocking properties warrant caution. Lemborexant was specifically studied in adults aged 55 and older in SUNRISE-1, providing direct safety data in this population. Neither drug appears on the Beers list as a high-risk medication, but both require dose consideration in geriatric patients [14].

Who Should Consider Dayvigo Over Trazodone

The choice between these medications depends on clinical context, insurance status, and individual risk factors.

Dayvigo May Be Preferred When

Patients have failed or cannot tolerate generic hypnotics (zolpidem, suvorexant, trazodone). Patients want a medication with strong RCT evidence for both sleep onset and maintenance. Patients are concerned about next-day cognitive impairment. The patient has commercial insurance with Dayvigo formulary coverage or qualifies for the manufacturer copay card.

Trazodone May Be Preferred When

Cost is a primary barrier. Patients are uninsured or underinsured. The patient has comorbid depression or anxiety that might benefit from low-dose serotonergic activity. The patient needs an unscheduled medication (relevant for prescribers in states with stricter controlled-substance regulations). The patient has a history of substance use disorder, where a non-scheduled medication may be preferred by the treatment team.

When Neither Is First-Line

The AASM 2017 guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults, ahead of any pharmacotherapy [8]. Dr. Andrew Krystal, who served as lead investigator on the SUNRISE-1 trial, has stated: "Pharmacotherapy for insomnia should be considered when CBT-I is unavailable, ineffective, or when the patient's clinical situation requires more rapid symptom relief" [1]. The Endocrine Society and AASM both emphasize that sleep disorders in patients receiving hormone therapy should be evaluated for underlying hormonal contributors before initiating standalone hypnotic treatment [15].

Generic Availability and Future Pricing Outlook

Dayvigo's patent field suggests that a generic version of lemborexant is unlikely before 2032 at the earliest, based on Eisai's listed patents in the FDA Orange Book [5]. Until then, the price gap between these two options will persist.

Trazodone's generic market is mature. Over a dozen manufacturers produce it in the United States, and prices have been stable for years. Biosimilar or authorized-generic competition is not applicable because trazodone is a small molecule, not a biologic.

For patients currently paying out of pocket for Dayvigo, the arrival of suvorexant generics (expected in the late 2020s as Merck's patents on Belsomra expire) could provide a lower-cost DORA alternative, though suvorexant and lemborexant differ in receptor binding kinetics and half-life [10].

Patients considering a switch between the two drugs should discuss timing and washout with their prescriber. Because lemborexant and trazodone act on different receptor systems, there is no pharmacological cross-tolerance, but abrupt discontinuation of either medication after prolonged use warrants clinical oversight.

The American Academy of Sleep Medicine 2017 guideline recommendation for CBT-I as first-line therapy for chronic insomnia remains the standard of care regardless of which pharmacotherapy a patient and provider select [8]. Patients spending over $100 per month on a sleep medication should ask their prescriber whether a CBT-I referral, formulary alternative, or manufacturer assistance program could reduce that cost without sacrificing clinical outcomes.